Results 201 to 210 of about 4,132 (265)

Safety and Efficacy of Aumolertinib as First‐Line Treatment in EGFR‐Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single‐Arm, Prospective Phase II Study (ARISE Study)

open access: yesMedComm, Volume 7, Issue 8, August 2026.
Aumolertinib treatment resulted in improved clinical activity in EGFR‐mutant ASC. ABSTRACT Lung adenosquamous carcinoma (ASC) is a rare histological subtype of non‐small cell lung cancer (NSCLC), and prospective data regarding the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in this patient population remain ...
Longfeng Zhang   +10 more
wiley   +1 more source

Reactive Cutaneous Capillary Endothelial Proliferation in Esophageal Squamous Cell Carcinoma Patients Treated With Camrelizumab‐Based Therapy: A Pooled Analysis of Two Phase 3 Trials

open access: yesMedComm, Volume 7, Issue 8, August 2026.
Camrelizumab‐induced reactive cutaneous capillary endothelial proliferation (RCCEP) was frequent yet manageable in patients with advanced esophageal squamous cell carcinoma and correlated with improved response and survival, suggesting RCCEP as a potential on‐treatment biomarker of clinical benefit.
Jia Liu   +11 more
wiley   +1 more source

Graded chronic noncancer pain distribution using the Graded Chronic Pain Scale-Revised framework: a cross-sectional study. [PDF]

open access: yesPain Rep
Hellmann SS   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy